Clinical Trial Update: Natalizumab Temporary Discontinuation Study [Phase 4]

View source ↗

Summary

A Phase 4 study assessing temporary discontinuation of natalizumab in people with multiple sclerosis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• Tysabri (Natalizumab)

Snippet

Sponsor: University at Buffalo | Conditions: Multiple Sclerosis | Phase 4 | Status: COMPLETED